熱門資訊> 正文
TG Therapeutics宣布1亿美元股票回购计划
2025-09-04 01:40
- TG Therapeutics (NASDAQ:TGTX) announced on Wednesday that its board authorized a new share repurchase program to buy back shares worth up to $100M from time to time through open-market purchases and other transactions.
- The program highlights its resolve to generate value for its shareholders and indicates management’s view that TGTX stock doesn’t adequately reflect the “multibillion-dollar potential” of its lead asset, Briumvi, or the company’s long-term prospects, the biotech said.
- The announcement coincided with the completion of TG’s (NASDAQ:TGTX) previously authorized $100M share buyback program, under which the company has repurchased nearly 3.5M shares at $28.55 per share on average since its launch in August 2024.
- CEO Michael Weiss added that during the month of August alone, the company could buy back roughly $78M worth of TGTX shares at attractive prices.
More on TG Therapeutics
- TG Therapeutics: Looking For The Stimulus For A Turnaround
- TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript
- The Play On TG Therapeutics
- TG Therapeutics falls after Q2 miss despite guidance raise
- TG Therapeutics raises BRIUMVI 2025 revenue guidance to $575M while advancing subcutaneous pipeline
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
